<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099628</url>
  </required_header>
  <id_info>
    <org_study_id>DiTECT-HAT-WP3</org_study_id>
    <nct_id>NCT04099628</nct_id>
  </id_info>
  <brief_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring</brief_title>
  <acronym>DiTECT-HAT-WP3</acronym>
  <official_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Sante Publique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIRDES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines the feasibility, diagnostic performance and cost for monitoring of&#xD;
      eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of&#xD;
      serological and molecular high throughput tests with and without previous rapid diagnostic&#xD;
      test blood screening for early detection of Trypanosoma brucei gambiense HAT re-emergence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, the prevalence of Trypanosoma brucei gambiense (Tbg) human African&#xD;
      trypanosomiasis (HAT) has fallen and HAT has been targeted for elimination. At low disease&#xD;
      prevalence, HAT control is increasingly integrated into routine activities of peripheral&#xD;
      health centres. However, the weak capacity of fixed health structures to implement control&#xD;
      activities, lack of coverage, the unspecific clinical picture of HAT, and the existence of&#xD;
      asymptomatic cases and animal reservoirs may result in under detection of HAT. To ensure&#xD;
      sustainability of zero transmission and to avoid re-emergence caused by remaining Tbg&#xD;
      reservoirs, continued post-elimination monitoring is therefore required.&#xD;
&#xD;
      Health workers performing house to house visits in foci with very low HAT prevalence can&#xD;
      easily collect blood on filter paper and send it to regional HAT reference centres for&#xD;
      analysis. The objective of the DiTECT-HAT-WP3 study is to determine the feasibility and cost&#xD;
      of diagnostic algorithms of serological and molecular high-throughput tests on blood on&#xD;
      filter paper for post-elimination monitoring, with or without a previous screening with rapid&#xD;
      diagnostic tests.&#xD;
&#xD;
      In villages in low to zero prevalence foci in Democratic Republic (DR) Congo, Côte d'Ivoire&#xD;
      and Burkina Faso, a health worker will go from house to house to 1) register all consenting&#xD;
      inhabitants in a Personal Digital Assistant; 2) take a blood sample on filter paper 3)&#xD;
      perform 3 rapid diagnostic tests. All dried blood spots (DBS) are sent to the reference&#xD;
      laboratory for high-throughput testing (ELISA, trypanolysis, loop-mediated isothermal&#xD;
      amplification method (LAMP) and real time (RT) -PCR). Subjects positive in at least 1 test -&#xD;
      the RDTs or high-throughput tests - are revisited twice for parasitological confirmation.&#xD;
&#xD;
      In each country, blood specimens of 6000 persons will be tested. The relative effectiveness&#xD;
      and overall cost of the different diagnostic algorithms will be investigated. We will&#xD;
      quantify the break-even point for an imperfect test algorithm by formulating a decision&#xD;
      criterion to assess how many false negatives, but particularly how many false positives can&#xD;
      be tolerated while still achieving an intervention with a reasonable cost burden. The results&#xD;
      will enable us to propose a test algorithm and a threshold to send out specialised mobile&#xD;
      teams for stopping HAT re-emergence, without unnecessarily raising the alarm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential assignement</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 3 RDTs on fresh blood, immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.&#xD;
Reference standard: for index test positives only: combined results of 2 parasitological examinations. Subjects negative in all index tests are considered HAT negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk</measure>
    <time_frame>6 months</time_frame>
    <description>Index tests: 3 RDTs on fresh blood, immune trypanolysis on DBS, ELISA on DBS, LAMP on DBS, RT-PCR on DBS.&#xD;
Reference standard: for index test positives only: combined results of 2 parasitological examinations. Subjects negative in all index tests are considered HAT negative.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Human African Trypanosomiasis</condition>
  <condition>Sleeping Sickness</condition>
  <condition>Trypanosoma Brucei Gambiense; Infection</condition>
  <condition>West African Sleeping Sickness</condition>
  <condition>African Trypanosomiases</condition>
  <condition>Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense</condition>
  <arm_group>
    <arm_group_label>Diagnostic tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid diagnostic test (RDT); Serological and molecular tests on DBS</intervention_name>
    <description>The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.&#xD;
Other Names:&#xD;
rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)</description>
    <arm_group_label>Diagnostic tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated for HAT (irrespective of time elapsed since treatment)&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  &lt; 4 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veerle Lejon, PhD, HDR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Rechercher pour le Développement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIRDES</name>
      <address>
        <city>Bobo Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Programme Nationale de Lutte contre la trypanosomiase humaine Africaine</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Pierre Richet, Institut National de Santé Publique</name>
      <address>
        <city>Bouaké</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monitoring</keyword>
  <keyword>surveillance</keyword>
  <keyword>re-emergence</keyword>
  <keyword>rapid diagnostic test</keyword>
  <keyword>trypanolysis</keyword>
  <keyword>LAMP</keyword>
  <keyword>ELISA</keyword>
  <keyword>molecular biology</keyword>
  <keyword>RT-PCR</keyword>
  <keyword>serology</keyword>
  <keyword>diagnosis</keyword>
  <keyword>specificity</keyword>
  <keyword>sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Trypanosomiasis, African</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

